Table II.
Baseline and other characteristics of patients with pulmonary AEs according to treatment group.
| Patients with pulmonary AEs |
Patients without pulmonary AEs |
|||
|---|---|---|---|---|
| Characteristic | Ticagrelor, n = 369 | Clopidogrel, n = 390 | Ticagrelor, n = 8866 | Clopidogrel, n = 8796 |
| Baseline characteristics | ||||
| Age, years, median (Q1–Q3) | 67 (60–75) | 69 (61–76) | 62 (54–70) | 62 (54–70) |
| Female, n (%) | 91 (24.7) | 115 (29.5) | 2543 (28.7) | 2488 (28.3) |
| Weight, kg, median (Q1–Q3) | 80 (70–90) | 76 (67–87) | 80 (70–90) | 80 (70–90) |
| Race Caucasian, n (%) | 340 (92.1) | 343 (87.9) | 8139 (91.8) | 8077 (91.8) |
| Habitual smoker, n (%) | 120 (32.5) | 111 (28.5) | 3207 (36.2) | 3175 (36.1) |
| Diabetes mellitus, n (%) | 124 (33.6) | 132 (33.8) | 2181 (24.6) | 2184 (24.8) |
| Congestive heart failure, n (%) | 36 (9.8) | 44 (11.3) | 471 (5.3) | 490 (5.6) |
| Non-haemorrhagic stroke, n (%) | 13 (3.5) | 34 (8.7) | 335 (3.8) | 328 (3.7) |
| Peripheral arterial disease, n (%) | 36 (9.8) | 48 (12.3) | 523 (5.9) | 521 (5.9) |
| Chronic renal disease, n (%) | 41 (11.1) | 39 (10.0) | 332 (3.7) | 363 (4.1) |
| Final diagnosis | ||||
| ST-elevation MI, n (%) | 124 (33.6) | 145 (37.2) | 3357 (37.9) | 3360 (38.2) |
| Non ST-elevation MI, n (%) | 197 (53.4) | 188 (48.2) | 3772 (42.6) | 3726 (42.4) |
| Unstable angina/other, n (%) | 48 (13.0) | 57 (14.6) | 1490 (16.8) | 1508 (17.2) |
| Revascularisation | ||||
| Primary PCI for ST-elevation MI, n (%) | 88 (23.8) | 102 (26.2) | 2658 (30.0) | 2681 (30.5) |
| Other PCI before discharge for index event, n (%) | 97 (26.3) | 95 (24.4) | 2832 (31.9) | 2779 (31.6) |
| CABG pre-discharge, n (%) | 77 (20.9) | 78 (20.0) | 388 (4.4) | 422 (4.8) |
| Other management | ||||
| No clopidogrel prior to randomisation, n (%) | 200 (54.2) | 216 (55.4) | 5158 (58.2) | 5117 (58.2) |
| Premature study drug discontinuation, n (%) | 161 (43.6) | 161 (41.3) | 2025 (22.8) | 1836 (20.9) |